Clik here to view.
Provectus gets Chinese process patent allowance
Provectus Biopharmaceuticals (NYSE MKT:PVCT) has received notification of allowance from the Chinese Patent Office for its application protecting the synthetic process used to produce the small...
View ArticleClik here to view.
Provectus taking novel path to treat cancer
Rather than taking a biochemistry approach to develop drugs that kill cancer cells, Provectus Biopharmaceuticals (NYSE MKT:PVCT) is using physical chemistry by harnessing the unique properties of Rose...
View ArticleClik here to view.
Provectus prices $13.1-million offering
Provectus Biopharmaceuticals (NYSE MKT:PVCT) has priced a public offering of 17.5 million shares of common stock and warrants to purchase an additional 17.5 million shares at a price of 75 cents for a...
View ArticleProvectus taking novel path to treat cancer
Rather than taking a biochemistry approach to develop drugs that kill cancer cells, Provectus Biopharmaceuticals (NYSE MKT:PVCT) is using physical chemistry by harnessing the unique properties of Rose...
View Article
